Pfizerの空売り状況は、投資家がPfizerの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Pfizer (NYSE:PFE) 株価情報, 空売り情報

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Options

Markets

資金力を持つ投資家たちは、ファイザー（NYSE:PFE）に対して積極的なアプローチをとっており、市場プレイヤーが無視すべきではないと言えるでしょう。 Benzingaが公開したオプションの記録を追跡したところ、今日この重要な動きが明らかになりました。

ファイザーのオプション取引｜慎重な取引を

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVX#NASDAQ">NAVX</a>) stock traded higher on Wednesday.
In an SEC filing, Novavax <a target="_blank" href="https://www.benzinga.com/secfilings/25/04/44946464/novavax-inc-general-corporate-statement-form8" rel="noreferrer noopener">said</a>, &#8220;We believe that our Biologics License Application (BLA) is approvable based on conversations with U.S. Food and Drug Administration (FDA), as of our Prescription Drug User Fee Act date on <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">April 1 and through today</a>.&#8221;
The company said that it received formal communication from the FDA in the form of an information request for a post-marketing commitment to generate additional clinical data.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" rel="noreferrer noopener">Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst</a>
&#8220;We look forward to engaging with the FDA expeditiously to address the PMC request and move to approval as soon as possible,&#8221; the company <a target="_blank" href="https://www.benzinga.com/secfilings/25/04/44946464/novavax-inc-general-corporate-statement-form8" rel="noreferrer noopener">said</a> in the SEC filing on Wednesday.&nbsp;&nbsp;
According to a media report in early April, the regulators missed the deadline for deciding to grant full <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613147/fda-delays-full-approval-decision-on-novavaxs-covid-19-vaccine" rel="noreferrer noopener">approval to Novavax&#8217;s shot</a>.
The Wall Street Journal reports that the agency is now delaying the decision and has reportedly requested more data, making it unlikely that the application will be approved soon, according to sources.
In April, Novavax released preliminary results from the SHIELD-Utah&nbsp;study investigating the effects of systemic and local reactogenicity of COVID-19&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44824383/novavax-covid-vaccine-shows-milder-side-effects-than-pfizer-biontechs-shot-study" rel="noreferrer noopener">vaccine doses in&nbsp;Utah</a>.
SHIELD-Utah&nbsp;was a prospective, interventional study conducted at the&nbsp;University of Utah&nbsp;Health.
The study showed Novavax's COVID-19 Vaccine, Adjuvanted (2024-2025 Formula), targeting the JN.1 strain, resulted in fewer and less severe reactogenicity symptoms when compared with the&nbsp;Pfizer Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)-BioNTech SE's&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44808832/shield-utah-study-shows-novavaxs-covid-19-vaccine-induces-lower-reactogenicity-symptoms-compared-t" rel="noreferrer noopener">mRNA 2024-2025 vaccine</a>.
In September 2024, the U.S. Food And Drug Administration (FDA) granted Emergency Use Authorization to&nbsp;Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants" rel="noreferrer noopener">individuals aged 12 and older</a>.
Novavax&#8217;s vaccine was included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on&nbsp;June 27, 2024.
<h2 class="wp-block-heading">Novavax Stock Prediction For 2025</h2>
Equity research analysts, both on and off Wall Street, typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Novavax, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. 
For Novavax, the 200-day moving average sits at $9.94, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $7.33. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: NVAX stock was up 19.5% at $7.47 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs" target="_blank" rel="noreferrer noopener">Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

News

Health Care

Movers

Trading Ideas

General

BNTX

NAVX

NVAX

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

Summit Therapeutics Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) partner, Akeso, Inc., released topline data from the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Phase 3 HARMONi-6/K112-306 trial</a> on Wednesday.
The trial is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44944372/ivonescimab-in-combination-with-chemotherapy-achieves-statistically-significant-superiority-in-pfs" rel="noreferrer noopener">irrespective of PD-L1 expression</a>.
HARMONi-6 is a study conducted in China sponsored by Akeso with all relevant data exclusively generated, managed, and analyzed by Akeso.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44463128/analyst-initiates-coverage-on-undervalued-summit-therapeutics" rel="noreferrer noopener">Analyst Initiates Coverage On ‘Undervalued' Summit Therapeutics</a>
The trial met its primary endpoint of progression-free survival (PFS).
At a prespecified interim analysis conducted by an Independent Data Monitoring Committee, ivonescimab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS compared to BeiGene, Ltd's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>) Tevimbra (tislelizumab) plus chemotherapy.
The PFS benefit was demonstrated in patients with either PD-L1-positive or PD-L1-negative tumors.
Akeso noted that this Phase 3 study identified no new safety signals.
The full data set for HARMONi-6 will be presented at an upcoming major medical conference later this year.
The companies add that before HARMONi-6, there were no known Phase 3 trials in NSCLC that showed a statistically significant improvement compared to PD-(L)1 inhibitor therapy in combination with chemotherapy in a head-to-head setting.
Summit is currently enrolling patients in the HARMONi-3 Phase 3 study sponsored by Summit to evaluate ivonescimab combined with chemotherapy compared to Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) combined with chemotherapy in patients with first-line metastatic, squamous and non-squamous NSCLC.
In September 2024, Summit Therapeutics&nbsp;released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41724651/summit-therapeutics-unique-investment-in-oncology-lead-drug-candidate-shows-promise" rel="noreferrer noopener">conducted in China</a>.
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial's primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40771038/summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-ris" rel="noreferrer noopener">hazard ratio (HR) of 0.51</a>.
In February, Summit Therapeutics announced a clinical trial collaboration with Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)&nbsp;to evaluate ivonescimab with several of Pfizer's antibody-drug conjugates (ADCs) across <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43907587/summit-therapeutics-announces-clinical-trial-collaboration-with-pfizer-to-evaluate-ivonescimab-in-" rel="noreferrer noopener">multiple solid tumor settings</a>.
Under the terms of the agreement, Summit will provide ivonescimab for use in the proposed studies, and Pfizer will be responsible for conducting the studies' operations. Summit and Pfizer will oversee the studies. Both parties retain their respective rights to their products. The studies combining ivonescimab with Pfizer's vedotin ADCs are planned to begin in the middle of this year.
Price Action: SMMT stock is up 21.11% at $33.11 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44952308/boston-scientific-raises-annual-outlook-after-strong-heart-devices-sales-in-q1-announces-cfo-transition" target="_blank" rel="noreferrer noopener">Boston Scientific Raises Annual Outlook After Strong Heart Devices Sales In Q1, Announces CFO Transition</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Large Cap

SMMT

Why Is Summit Therapeutics Stock Soaring On Wednesday?

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
What Happened:&nbsp;The Trump Administration is&nbsp;contemplating a policy to align U.S. drug prices with lower rates in other developed countries. The policy is likely to be enforced by the agency responsible for&nbsp;Medicare and Medicaid health programs, reported Reuters&nbsp;citing sources from the pharmaceutical industry.
The sources highlighted this policy as the pharmaceutical industry&#8217;s primary concern, surpassing other government actions under consideration, such as tariffs on imported medicines. One source labeled it as the most significant &#8220;existential&nbsp;threat to the industry and&nbsp;U.S. biosciences innovation.&#8221;
Though the Trump Administration hasn't directly addressed reference pricing, the conservative America First Policy Institute suggested it could be included in Medicare's drug price negotiations.
The industry trade group, PhRMA, has already approached Congress earlier this year regarding this issue, known as international reference pricing. The first source expressed apprehension about the potential upheaval this policy could trigger in the healthcare market, beyond just pharmaceuticals.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/44935195/elizabeth-warren-says-if-trump-illegally-fires-fed-chair-powell-hell-crash-our-markets-cause-more-economic-p" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says, &#8216;If Trump Illegally Fires Fed Chair Powell, He&#8217;ll Crash Our Markets, Cause More Economic Pain To American Families&#8217;</a>
Why It Matters: Under Biden&#8217;s Inflation Reduction Act, the U.S. began negotiating prices for its costliest drugs. However, the negotiated prices for the first 10 drugs remain over twice as high—and sometimes five times higher—than what drugmakers charge in other wealthy nations. During his first term, President Donald Trump&#8216;s attempt to implement an international reference pricing program was halted by a court ruling.
The current report by Reuters comes on the heels of President Trump&#8217;s executive order <a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">aimed </a>at lowering drug prices and reducing Medicare costs signed earlier this month. The order instructed the Secretary of Health and Human Services to seek guidance for the Medicare Drug Price Negotiation Program for the initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028. 
This potential move is perceived as a major threat to the pharmaceutical industry. Boston University's Rena Conti told Reuters that drugmakers might respond to international reference pricing by raising prices in reference countries, potentially justifying higher U.S. prices and increasing global revenue.
Invesco Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) and iShares U.S. Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) declined 8.6% and 7.5%, respectively over the past month.
Price Action: During the pre-market session on Wednesday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) gained 2.39%, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) climbed 1.16% and 1.07%, respectively. Meanwhile, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) edged 0.48% higher.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing" target="_blank" rel="noreferrer noopener">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing? &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Administration Considers Lowering US Drug Prices To International Levels: Report

Ratings for Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $27.17, a high estimate of $33.00, and a low estimate of $24.00. Observing a downward trend, the current average is 10.62% lower than the prior average price target of $30.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1745326862_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Pfizer by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Carter Gould &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Neutral &#x7C; $24.00&#x7C;- &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $24.00&#x7C;$28.00 &#x7C; 
&#x7C;Asad Haider &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $25.00&#x7C;$32.00 &#x7C; 
&#x7C;Vamil Divan &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $33.00&#x7C;$33.00 &#x7C; 
&#x7C;Colin Bristow &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $28.00&#x7C;$29.00 &#x7C; 
&#x7C;Andrew Baum &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $29.00&#x7C;$30.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pfizer. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pfizer compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Pfizer's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Pfizer's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PFE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pfizer analyst ratings.</a>
<h2>Discovering Pfizer: A Closer Look</h2>
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
<h3>Pfizer: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Pfizer showcased positive performance, achieving a revenue growth rate of 21.93% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Pfizer's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pfizer's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Pfizer's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.19%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.72, Pfizer adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Forecasting The Future: 6 Analyst Projections For Pfizer

Cantor Fitzgerald analyst Carter Gould initiates coverage on Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) with a Neutral rating and announces Price Target of $24.

Price Target

Initiation

Cantor Fitzgerald Initiates Coverage On Pfizer with Neutral Rating, Announces Price Target of $24

Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is scheduled to release its first quarter 2025 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">earnings on 29 April</a>.
Analysts forecast adjusted earnings of 70 cents per share with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44377465/pfizer-invites-public-to-view-and-listen-to-webcast-of-april-29-conference-call-with-analysts" rel="noreferrer noopener">sales of $14.26 billion</a>.
BofA updated its earnings model for 1Q25 as analyst Tim Anderson lowered total revenue estimates by -2.1%, primarily due to updated assumptions regarding the impact of Part D on the portfolio and tweaks to Paxlovid seasonality. EPS follows, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">decreasing by -4.9%</a>.
For 2025 and 2026, BofA increased total revenue estimates slightly (&lt;1%), partly related to updated FX assumptions and smaller product-level revisions. The analyst increased EPS estimates by +1.2% and +5.3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Citing a relative pharma group whose P/E multiple has recently declined due to tariff and drug pricing fears, BofA has reduced Pfizer&#8217;s price target from $29 to $26, reiterating its Neutral rating.
Pfizer&#8217;s stock is trading at about 7 times its expected 2024 earnings, which is lower than the peer average of around 11 times (excluding Eli Lilly and Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>)).
It also offers a high dividend yield of about 8%, which could help keep the stock price from falling much further. The BofA analyst notes that the long-term growth outlook is weaker than average due to upcoming patent expirations and rising competition for some of its key products.
Anderson says the focus of the earnings call will likely include:
<ul>
<li>A few months into the new administration, there is still uncertainty about how agencies like the Department of Health and Human Services (HHS) and the Centers for Medicare &amp; Medicaid Services (CMS) will operate under new leadership.
<ul>
<li>This matters for Pfizer, as around 12% of its total revenue comes from vaccine sales in the U.S. So far, the company's 2025 guidance does not factor in any potential changes to U.S. health policy.</li>
</ul>
</li>
<li>Pfizer has manufacturing facilities in Belgium, Germany, India, Ireland, Italy, Japan, and Singapore. Like many other companies, it hasn't commented yet on how possible <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">pharmaceutical tariffs</a> might affect its profit margins or earnings per share. Analysts will likely get the best chance to ask management about this during the first-quarter 2025 earnings call.
<ul>
<li>&#8220;Our belief is that most/all companies will likely not quantify any potential impact at the moment,&#8221; Anderson writes.</li>
</ul>
</li>
<li>After the recent setback with danuglipron, the company still has an oral GLP-1 drug in early development and a GIPR blocker <a href="https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient" target="_blank" rel="noreferrer noopener">in Phase 2 trials</a>.
<ul>
<li>However, if Pfizer is serious about expanding in the obesity space, it will likely need to consider mergers, acquisitions, or other business deals to strengthen its position.</li>
</ul>
</li>
</ul>
Price Action: PFE stock is down 0.88% at $21.95 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44903362/american-express-solid-revenue-and-spending-trends-drive-analyst-optimism" target="_blank" rel="noreferrer noopener">American Express&#8217; Solid Revenue, Spending Trends Drive Analyst Optimism</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

Guidance

Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline

Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally.
It will report its Q1 2025 earnings on April 29. Wall Street analysts expect the company to post EPS of $0.70, down from $0.82 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $14.27 billion, down from $14.88 billion a year earlier.
The 52-week range of Pfizer stock price was $20.92 to $31.54.
Pfizer's dividend yield is 7.66%. It paid $1.72 per share in dividends during the last 12 months.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
<h2 class="wp-block-heading">The Latest On Pfizer</h2>
On Feb. 4, the company announced its Q4 2024 earnings, posting adjusted EPS of $0.63, beating the consensus estimate of $0.47, as reported by <a href="https://www.benzinga.com/general/biotech/25/02/43463168/pfizer-q4-earnings-revenue-and-eps-beat-seagen-and-covid-19-products-show-strength-issues-strong-fy25-outlook">Benzinga</a>.
The U.S. drugmaker reported sales of $17.76 billion, up 22% year-over-year, and above the consensus of $17.40 billion.
Pfizer reaffirmed its full-year 2025 revenue guidance of $61 billion to $64 billion, compared to the consensus estimate of $63.025 billion. The company anticipates adjusted EPS in the range of $2.80 to $3.00, compared to the consensus of $2.94.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As A Pfizer Investor?</h2>
If you want to make $100 per month — $1,200 annually — from Pfizer dividends, your investment value needs to be approximately $15,666, which is around 698 shares at $22.44 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (7.66% in this case). So, $1,200 / 0.0766 = $15,666 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find Pfizer stock an attractive option for making a steady income of $100 per month by owning 698 shares of stock. There may be more upside to come as investors benefit from the company's consistent dividend hikes. Pfizer has raised its dividend consecutively for the last 14 years.&nbsp;
Check out this <a href="https://www.benzinga.com/personal-finance/25/04/44830336/how-kimberly-clark-txnm-energy-and-getty-realty-can-put-cash-in-your-pocket">article by Benzinga</a> for three more stocks offering high dividend yields.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/investing-in-the-midwest-why-multifamily-real-estate-is-a-winning-strategy">This investment company boasts a 33.85% internal rate of return (IRR) for its realized projects, allowing accredited investors to earn passive returns and avoid the headaches of being a landlord.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

How To Put $100 In Your Retirement Fund Each Month With Pfizer Stock

These mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) shares escalated 119.05%. The stock debuted on the <a href="https://www.benzinga.com//node/44876727" target="_blank" rel="noreferrer noopener">Nasdaq earlier last week</a>.</li>
<li>Hertz Global Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) shares skyrocketed 99.03% after Bill Ackman&#8217;s Pershing Square Capital Management filed an amended 13F showing that the firm purchased 12.71 million shares of the rental car company as of Dec. 31, representing <a href="https://www.benzinga.com//node/44853443" target="_blank" rel="noreferrer noopener">a stake of approximately 4.1%</a>.</li>
<li>Metsera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) stock is jumping 49.62% after Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) discontinued <a href="https://www.benzinga.com//node/44790653" target="_blank" rel="noreferrer noopener">the development of danuglipron</a>.</li>
<li>Vista Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIST#NYSE">VIST</a>) shares surged 35.52% after the company announced it acquired Petronas E&amp;P Argentina through a mixed transaction consisting of $900 million in cash, $300 million in deferred payments, and <a href="https://www.benzinga.com//node/44848713" target="_blank" rel="noreferrer noopener">approximately 7.3 million ADS units</a>.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock upped 34.63% after the company issued a year-over-year increase in its first-quarter revenue guidance and announced a $100 million share repurchase program. Additionally, the company announced it launched a non-animal navigator solution to help drug developers <a href="https://www.benzinga.com//node/44798103" target="_blank" rel="noreferrer noopener">reduce reliance on animal testing.</a></li>
<li>Sibanye-Stillwater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) shares 27.76%, probably amid a rally in the value of the commodity past the price of $3300 and towards an all-time high.</li>
<li>Banco Macro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMA#NYSE">BMA</a>) stock increased 27.71%.</li>
</ol>
Photo by via Shutterstock

Equities

Mid Cap

BULL

CERT

MTSR

SBSW

VIST

ZLAB

Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio?

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>.
In June 2024, ACIP postponed a vote on a recommendation for adults aged 50-59 at increased risk for RSV-LRTD until additional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39522040/cdc-advisor-panel-recommends-rsv-shots-in-us-for-people-above-75-years-analyst-says-decision-nega" rel="noreferrer noopener">data becomes available</a>.
The update includes Pfizer Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Abrysvo (Respiratory Syncytial Virus Vaccine), which the U.S. Food and Drug Administration approved in October 2024 for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41493556/fda-approves-pfizers-respiratory-syncytial-virus-vaccine-abrysvo-for-adults-below-60-years" rel="noreferrer noopener">risk of severe disease</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
The recommendation also includes GSK plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Arexvy in adults aged 50-59 who are at increased risk <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44853850/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-" rel="noreferrer noopener">for severe RSV disease</a>.
This expands on ACIP&#8217;s previous vote in June 2024 to recommend RSV vaccines for adults aged 60-74 who are at increased risk and all adults aged 75 and older.
Arexvy is indicated for the prevention of LRTD caused by RSV in individuals 60 years of age and older and individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
According to the CDC, between 15,000 &#8211; 20,000 RSV-associated hospitalizations occur annually in U.S. adults <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44852139/acip-votes-to-expand-recommendation-for-pfizers-rsv-vaccine-abrysvo-to-include-adults-aged-50-to-5" rel="noreferrer noopener">aged 50 &#8211; 59 years</a>.
A systematic review of studies in the U.S. shows that RSV is estimated to cause 42,000 hospitalizations each year in adults aged 50-64 years old.
GSK said the ACIP considered results from a phase 3 trial evaluating the immune response and safety of GSK&#8217;s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to certain underlying medical conditions compared to older adults aged 60 years and older where efficacy has been demonstrated after a single dose of GSK&#8217;s RSV vaccine.
The updated recommendation does not benefit Moderna Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mRNA-based RSV vaccine mRESVIA (mRNA-1345), which is currently approved for adults over 60 years.
William Blair notes Moderna shared Phase 3 data for mRNA-1345 in high-risk adults aged 18-59 at its 2024 R&amp;D Day event and has since submitted an application to the FDA for regulatory approval using a priority review voucher.&nbsp;The FDA <a target="_blank" href="https://investors.modernatx.com/news/news-details/2025/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results-and-Provides-Business-Updates/default.aspx" rel="noreferrer noopener">has</a> accepted Moderna&#8217;s application and has assigned a PDUFA goal date of June 12, 2025.
Analyst Myles R. Minter highlights the Phase 3 trial of mRNA-1345 in over 1,000 high-risk individuals between ages 18 and 59. mRNA-1345 demonstrated non-inferior immunogenicity compared to adults age 60 or older for neutralizing antibodies against both RSV-A and RSV-B and a tolerable safety profile.
&#8220;If approved on time, we believe mRESVIA could be added to the updated age group recommendation during the scheduled June 25-26, 2025, ACIP meeting,&#8221; Minter said.
Price Action: PFE stock is up 1.07% 22.28, MRNA stock is down 2.30% at $24.62, and GSK stock is up 1.74% at $35.98 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars</a></li>
</ul>
Photo by pedro7merino via Shutterstock

MRNA

US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years

Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Thursday reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, <a target="_blank" href="https://www.benzinga.com/25/04/44860903/eli-lillys-oral-glp-1-drug-orforglipron-hits-phase-3-goals-in-diabetes-trial-stock-shoots-higher" rel="noreferrer noopener">using the efficacy estimand</a>.
BofA Securities analyst Tim Anderson writes, &#8220;Arguably one of the biggest, most important, most closely-watched pipeline events in large cap biopharma has just played out. And it was favorable.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction" rel="noreferrer noopener">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a>
Anderson says the only other current oral GLP-1 drug is Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Rybelsus (semaglutide), a peptide with some limitations.
&#8220;The &#8220;key&#8221; with orforglipron is that it is a &#8220;small molecule&#8221; drug, meaning easy to scale and produce &#8211; recall past manufacturing problems with injectable GLP-1s (from Eli Lilly and Novo Nordisk),&#8221; Anderson adds.
An oral drug like this can help expand obesity treatment outside the U.S., especially in developing countries where keeping medications cold is difficult.
BofA writes Eli Lilly is mainly focusing on selling the oral version in markets outside the U.S., where prices need to be lower. Since oral drugs are easier and cheaper to produce, this makes sense.
&#8220;Positive results like these, in a skittish market, should be received well,&#8221; BofA writes.
BofA forecasts 2030 orforglipron sales of around $10 billion compared to a consensus of around $9 billion.
The analyst maintains the Buy rating, with a price forecast of $1,000.
Anderson writes, &#8220;On a macro perspective, we believe that given the strength of the Phase II data, positive Phase III ACHIEVE-1 efficacy results were expected. However, in light of Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) recent discontinuation of danuglipron, tolerability and hepatotoxicity have emerged as more important clinical attributes, in our view.&#8221;
Price Action: LLY stock is up 16.3% at $854.84 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44866751/forge-global-eyes-strategic-expansion-with-10m-accuidity-acquisition" target="_blank" rel="noreferrer noopener">Forge Global Eyes Strategic Expansion With $10 Million Accuidity Acquisition</a></li>
</ul>
Photo by shisu_ka via Shutterstock

Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential

Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump&#8216;s 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs) in the U.S. healthcare system.
What Happened: In a post on X, addressed to President Trump on Wednesday, Cuban cheered the order that aims to reform PBMs, entities that control 80% of U.S. prescriptions. He emphasized the potential of the order to save billions and improve patient wellness.
Cuban&#8217;s proposals include separating&nbsp;formularies from PBMs to focus&nbsp;on wellness, mandating transparency in&nbsp;claims data to improve patient&nbsp;outcomes, and eliminating&nbsp;specialty drug tiers that inflate&nbsp;costs. He also urged action on issues such as the 340B program's double-dipping, which a 2023 study estimated to cost hospitals $500 million each year.
&#8220;Make them about wellness, not pay for play like a grocery store endcap. This ends rebates and allows for net pricing. It also allows for better care and wellness,&#8221; stated the Shark Tank celebrity. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Gotta be honest. The <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> EO on healthcare and in particular, drug pricing could save hundreds of billions. Here is how: 1. Divorce formularies from PBMs. Require them to come from independent organizations with no economic incentive from the formulary Make them…
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1912628036668739778?ref_src=twsrc%5Etfw">April 16, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban, the founder of Cost Plus Drug Company, also criticized&nbsp;PBM tactics like biosimilar substitution&nbsp;calls, where they push doctors&nbsp;to prescribe pricier drugs for&nbsp;higher margins, a practice enabled&nbsp;by vertical integration. He referenced the&nbsp;1990s FTC concerns when pharmaceutical&nbsp;companies acquired PBMs, leading to&nbsp;mandated open formularies.
SEE ALSO: <a href="https://benzinga.com/news/global/25/04/44856008/china-dismisses-trumps-tariff-numbers-game-files-wto-complaint-talks-can-only-proceed-based-on-mutual" target="_blank" rel="noreferrer noopener">China Dismisses Trump&#8217;s Tariff &#8216;Numbers Game,&#8217; Files WTO Complaint: Talks Can Only Proceed Based On &#8216;Mutual Respect&#8217;</a>
Why It Matters: Trump&#8217;s executive order comes as part of a <a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">broader effort</a> to lower drug prices and reduce Medicare costs. The administration is set to negotiate prices for a second batch of 15 medications, including Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, along with Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) cancer treatments Ibrance and Xtandi
Additionally, the Trump administration has disclosed plans for a "major tariff" on <a href="https://www.benzinga.com/government/regulations/25/04/44847222/trump-administration-opens-probe-into-foreign-drug-imports-eyes-tariffs-under-national-security-law">foreign pharmaceuticals</a>. This move could potentially impact the pharmaceutical industry, with the U.S. Department of Commerce launching an investigation into the potential national security risks posed by the country's reliance on imported pharmaceuticals and key drug ingredients.
Meanwhile, Cuban, an outspoken critic of the Trump administration, has always pushed for affordable and universal healthcare. He has consistently pointed out the shortcomings of the <a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">U.S. healthcare system</a>, which is further complicated by large insurance companies and pharmacy benefit managers.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/04/44858847/nancy-pelosi-called-us-china-trade-a-job-loserold-remarks-reemerge-amid-trump-tariff-push" target="_blank" rel="noreferrer noopener">Nancy Pelosi Called US-China Trade &#8220;A Job Loser:&#8221; Old Remarks Reemerge Amid Trump Tariff Push</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">diet and exercise alone</a>.
Eli Lilly adds that Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44859676/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safet" rel="noreferrer noopener">complete a Phase 3 trial</a>.&nbsp;
The trial randomized 559 participants to receive either 3 mg, 12 mg, or 36 mg orforglipron or placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">Eli Lilly&#8217;s Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch</a>
Lilly said on Thursday that it expects to submit orforglipron for weight management to global regulatory agencies by the end of this year, with the submission for the treatment of type 2 diabetes anticipated in 2026.&nbsp;
In the first Phase 3 trial of the ACHIEVE program, orforglipron met the primary endpoint of superior A1C (blood sugar) reduction compared to placebo at 40 weeks, lowering A1C by an average of 1.3% to 1.6% from a baseline of 8.0%, using the efficacy estimand.
In a key secondary endpoint, more than 65% of participants taking the highest dose of orforglipron achieved an A1C less than or equal to 6.5%, below the American Diabetes Association&#8217;s defined threshold for diabetes.
In an additional key secondary endpoint, participants taking orforglipron lost an average of 16.0 lbs (7.9%) at the highest dose.
Given that participants had not yet reached a weight plateau when the study ended, it appears that full weight reduction had not yet been attained.
For the treatment-regimen estimand, each dose of orforglipron led to statistically significant A1C reductions.
In the key secondary endpoint for body weight, 12 mg and 36 mg doses led to statistically significant reductions.
<ul>
<li>A1C reduction: 1.2% (3 mg), 1.5% (12 mg), 1.5% (36 mg), 0.4% (placebo)</li>
<li>Percent weight reduction: 4.5% (3 mg), 5.8% (12 mg), 7.6% (36 mg), 1.7% (placebo)</li>
<li>Weight reduction: 4.2 kg (9.3 lbs; 3 mg), 5.2 kg (11.5 lbs; 12 mg), 7.2 kg (15.8 lbs; 36 mg), 1.5 kg (3.4 lbs; placebo)</li>
</ul>
The overall safety profile of orforglipron in ACHIEVE-1 was consistent with the established&nbsp;GLP-1&nbsp;class. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate.
The most common adverse events for participants treated with orforglipron (3 mg, 12 mg, and 36 mg, respectively) were diarrhea (19%, 21%, and 26%) vs. 9% with placebo, nausea (13%, 18% and 16%) vs. 2% with placebo, dyspepsia (10%, 20% and 15%) vs. 7% with placebo, constipation (8%, 17% and 14%) vs. 4% with placebo, and vomiting (5%, 7% and 14%) vs. 1% with placebo.
Overall treatment discontinuation rates due to adverse events were 6% (3 mg), 4% (12 mg), and 8% (36 mg) for orforglipron vs. 1% with placebo.
No hepatic safety signal was observed.
Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) oral danuglipron was tied to &#8220;high rates&#8221; of mild gastrointestinal side effects, leading to more than half of the patients across all dose groups&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient" rel="noreferrer noopener">dropping out from the trial</a>.&nbsp;
More results from the ACHIEVE Phase 3 clinical trial program will be shared later this year, along with findings from the ATTAIN Phase 3 clinical trial program evaluating orforglipron for weight management.
Price Action: LLY stock is up 11.3% at $817.99 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/44860240/unitedhealth-slashes-2025-outlook-on-medicare-funding-reductions-stock-crashes" target="_blank" rel="noreferrer noopener">UnitedHealth Slashes 2025 Outlook On Medicare Funding Reductions, Stock Crashes</a></li>
</ul>
Photo by Jonathan Weiss via Shutterstock

Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars

Government

Regulations

CDC Advisory Committee On Immunization Practices Voted To Expand Pfizer's RSV Vaccine ABRYSVO To Include Adults Aged 50 To 59 At Increased Risk Of Disease

US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">reduce Medicare costs</a>.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
<ul>
<li>This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.</li>
<li>Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
The White House is also <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/lowering-drug-prices-by-once-again-putting-americans-first/" rel="noreferrer noopener">targeting</a> the rising costs seniors face under Medicare. A new payment model will be tested within a year to obtain better value for high-cost drugs and biologicals, including those not subject to price negotiations.
Further, the administration wants to align Medicare payments with actual hospital acquisition costs through a national survey, with potential reimbursement adjustments following the results.
To reform Medicaid drug pricing, the administration will develop recommendations linking drug payments to their value and ensuring accurate rebate payments from manufacturers. The initiative also aims to assist states in managing spending while promoting innovation in Medicaid reimbursement.
Affordability for life-saving medications is another key focus: Community health centers will be required to offer insulin and epinephrine at or below discounted 340B prices to low-income individuals with high out-of-pocket costs or no insurance, with compliance tied to eligibility for future federal grants..
To address price manipulation in the supply chain, the administration calls for reevaluating middlemen roles, such as pharmacy benefit managers, and seeking transparency in their compensation structures. Within 90 days, recommendations to promote a more efficient pharmaceutical market are expected.
Other planned reforms include accelerating FDA approvals for generics and over-the-counter conversions, streamlining the drug importation program, and ensuring Medicare payments do not incentivize hospital-based care over less costly physician offices.
Lastly, federal agencies will investigate anti-competitive practices by drug manufacturers, with public listening sessions and policy recommendations expected within six months.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo by Aria Armoko via Shutterstock

ABBV

BIIB

BMRN

GILD

REGN

VRTX

Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction

Novavax, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) on Tuesday released preliminary results from the SHIELD-Utah&nbsp;study investigating the effects of systemic and local reactogenicity of COVID-19 <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">vaccine doses in&nbsp;Utah</a>.
SHIELD-Utah&nbsp;was a prospective, interventional study conducted at the&nbsp;University of Utah&nbsp;Health.
The study showed Novavax&#8217;s COVID-19 Vaccine, Adjuvanted (2024-2025 Formula), targeting the JN.1 strain, resulted in fewer and less severe reactogenicity symptoms when compared with the Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)-BioNTech SE&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44808832/shield-utah-study-shows-novavaxs-covid-19-vaccine-induces-lower-reactogenicity-symptoms-compared-t" rel="noreferrer noopener">mRNA 2024-2025 vaccine</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" rel="noreferrer noopener">Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst</a>
This real-world study, conducted between September and&nbsp;December 2024, also showed that the impact of symptoms on daily activities, including work and family responsibilities, was lower in recipients of Novavax&#8217;s vaccine.
&#8220;The risk of side effects or reactogenicity has been shown to be a major decision factor for those opting to get vaccinated. Our findings of lower frequency and intensity of reactogenicity symptoms from the protein-based COVID-19 vaccine observed in SHIELD-Utah&nbsp;add valuable insights to the public debate weighing choice and value of COVID-19 vaccination,&#8221; said&nbsp;Sarang K. Yoon, DO, MOH, Principal Investigator,&nbsp;University of Utah&nbsp;Health.
As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly fewer reactogenicity events than Pfizer-BioNTech recipients.
On average, Novavax recipients experienced 1.7 symptoms versus 2.8 systemic symptoms in Pfizer-BioNTech recipients.
43.8% of Pfizer-BioNTech recipients experienced at least one symptom of Grade 2 or higher compared to 24.2% of Novavax recipients.
Local reactogenicity events also showed an absolute difference of 12.5% fewer in Novavax recipients versus Pfizer-BioNTech recipients.
The impact of symptoms on daily activities, including work, showed the hours of reduced activity were lower in Novavax recipients versus Pfizer-BioNTech recipients (mean=0.7 vs. 1.4h and mean=0.8 vs. 2.4h for missed work and less productivity, respectively).
Earlier this month, the regulators missed the deadline for deciding to grant full approval to <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613147/fda-delays-full-approval-decision-on-novavaxs-covid-19-vaccine" rel="noreferrer noopener">Novavax&#8217;s COVID-19 shot</a>.
Price Action: NVAX stock is down 3.60% at $6.18 at the last check Tuesday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44820082/global-electric-vehicle-sales-jump-in-march-what-country-leads-in-sales" target="_blank" rel="noreferrer noopener">Global Electric Vehicle Sales Jump In March: What Country Leads In Sales?</a></li>
</ul>
Image: Shutterstock

Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study

When the market throws a delightful little soiree for the bears and headlines scream of doom, gloom and capital destruction, it often feels like it&#8217;s the end of it all.
But odds are the world is not going to end.
It was the same in previous bear markets.
During the 1998 Russian crisis and the collapse of Long Term Capital Management, closed-door meetings at the New York offices of the Federal Reserve were held, in which participants discussed who would pony up enough cash to save the financial system.
Warren Buffett passed. Instead, a bunch of Wall Street and a few French banks stepped up with the necessary cash.
During the Great Financial Crisis, it felt like the financial system&#8217;s implosion was always just seconds away.
In the initial stages of the COVID-19 pandemic, the end of the world was the lead story for weeks on end.
In every case, the world survived and stocks recovered.
In each case, this was the winning investment strategy during the bear market.
If the end does come, I suspect none of us will be concerned about our stock portfolio.
I do not recall Charlton Heston asking Cornelius or Zira about the price of IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) or General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) in Planet of the Apes.
Rick Grimes of The Walking Dead never takes a break from killing zombies to call his broker.
If the world survives the tariff war of 2025, we might want to make some of the moves that paid off in the aftermath of prior almost-end-of-the-world events.
One of the best strategies is buying dividends and dividend growth.
Investors who bought stocks like Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Altria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) and CapitalOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) in early 2009 not only locked in high levels of income, their gains over the next decade were spectacular.
Buying high-yield stocks like Unum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>), Tanger Outlets (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKT#NYSE">SKT</a>) and Marathon Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) in the spring of 2020 has also worked out extraordinarily well for investors who allowed rational thinking to overcome fear.
Unless the world ends, this time should offer the same opportunities to lock in high yields from companies that also offer the potential for outsized long-term gains.
Shares of Pfizer have once again fallen to levels that make the stock a high-yielding opportunity for patient investors.
Pfizer has a diverse drug portfolio and is in a strong position in the vaccine markets. Going forward, they are shedding the off-patent drug business to focus on innovation and newer products.
Pfizer generates massive amounts of free cash flow, which is used to pay down debt, buy back stock and pay dividends.
The company plans to pay out 50% of cash flow as dividends so the payout should continue to grow over time.
Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) is one of the best-positioned auto companies in the current environment and should do very well as the trade war progresses towards a conclusion.
Ford continues to dominate the pickup truck market and I don&#8217;t see that changing anytime soon.
Ford intends to have a presence in the EV market but will not abandon the traditional market anytime soon. The Mustang Mach-E and Lightning F-150 electric vehicles are both selling well and attracting customers who have never considered Ford products before.
Ford has focused on reducing debt and strengthening its balance sheet over the past few years, and this strategy is working.
The company currently has over $25 billion in cash and securities on the books.
The stock is currently yielding over 7% and has excellent long-term appreciation potential from current levels.
UPS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) shares have also fallen to the level where the dividend is attractive. At the current price, the yield is over 7%.
UPS seems like a solid bet, even with some bumps in the road ahead. They&#8217;re the big dog in package delivery, handling way more daily packages than FedEx in the US.
<h2 class="wp-block-heading">Volatile Markets Demand Speed: 60% Off Flash Sale</h2>
When the S&amp;P swings wildly, being first matters. Access breaking news up to 30 minutes before others, customized scanners, and instant alerts—all for 60% off. This flash sale won't survive in volatile markets—<a href="https://www.benzinga.com/pro/register-spring-sale">secure your discount </a>now!
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies which are neither expressly or impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

This Strategy Outperforms In Bear Markets

<a href="https://www.youtube.com/watch?v=Dt_sprpZXqk">https://www.youtube.com/watch?v=Dt_sprpZXqk</a>
&nbsp;

Global

President Trump Says Will Do Tariffs On Imported Pharmaceuticals; All I Have To Do Is Impose A Tariff; Pharmaceutical Tariffs In Not Too Distant Future

Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>),&nbsp;&nbsp;Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stocks are trading higher on Monday.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) announced on Monday that it will discontinue the development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">chronic weight management</a>.
A single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42827918/viking-therapeutics-structure-therapeutics-positioned-as-key-pharma-partners-for-weight-loss-products-analyst" rel="noreferrer noopener">Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst</a>
Pfizer is one of several drugmakers working to develop an alternative to injectable weight loss drugs. Still, it&#8217;s far behind rivals like Eli Lilly and Novo Nordisk, who already lead the market with weekly injections.
Eli Lilly is developing orforglipron, which could be the first small-molecule weight-loss pill when it launches in 2026. This would give Eli Lilly a two-year lead <a href="https://www.benzinga.com/general/biotech/24/10/41137681/eli-lilly-nears-first-trillion-pharma-title-but-investors-caution-amid-sky-high-valuation" target="_blank" rel="noreferrer noopener">before rivals catch up</a>.
In March, Viking Therapeutics completed subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company&#8217;s dual agonist of the GLP-1 and glucose-dependent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44490486/viking-therapeutics-announces-completion-of-enrollment-in-phase-2-venture-oral-dosing-trial-of-vk2" rel="noreferrer noopener">insulinotropic polypeptide (GIP) receptors</a>.
VK2375 is being developed in oral and subcutaneous formulations for various metabolic disorders, such as obesity. Viking expects to report data from the study in <a href="https://www.benzinga.com/general/biotech/24/11/41712739/viking-therapeutics-reveals-early-stage-from-experimental-oral-obesity-drug-showing-weight-loss-a" target="_blank" rel="noreferrer noopener">the second half of 2025</a>.
Viking plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the first half of 2025.
In June 2024, Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) unveiled 12-week topline obesity data from its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39144875/structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lillys-orforgli" target="_blank" rel="noreferrer noopener">Phase 2a study of GSBR-1290</a>.
In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39133591/structure-therapeutics-reports-positive-topline-data-from-its-phase-2a-obesity-study-and-capsule-t" rel="noreferrer noopener">6.2% at 12 weeks</a>.&nbsp;
In July 2024, Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39812408/roche-highlights-encouraging-data-from-newly-acquired-second-weight-loss-drug-candidate-in-early-" rel="noreferrer noopener">type 2 diabetes and obesity</a>.
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
This data is better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>.
In June 2023, Pfizer discontinued the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic data from Phase 1 studies and laboratory measurements of elevated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35757948/what-are-pfizers-prospects-in-obesity-pill-market-analysts-say-optimism-cautiousness-surround-wit" rel="noreferrer noopener">transaminases (liver enzymes)</a>.
In March, Altimmune Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) unveiled the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments&nbsp;for its <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44330443/altimmune-expands-weight-loss-drug-pemvidutides-potential-to-alcohol-related-disorders" rel="noreferrer noopener">obesity drug, pemvidutide</a>.
Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively.
Price Action: LLY stock is up 1.14% at $739.26, NVO stock is up 1.68% at $65.82, ALT stock is up 3.40% at $4.56, VKTX stock is up 13.5% at $25.21
GPCR stock is up 8.36% at $17.23 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44788755/bp-discovers-oil-at-far-south-prospect-in-deepwater-gulf-boosts-upstream-growth-outlook" target="_blank" rel="noreferrer noopener">BP Discovers Oil At Far South Prospect in Deepwater Gulf, Boosts Upstream Growth Outlook</a></li>
</ul>

GPCR

RHHBY

VKTX

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">chronic weight management</a>.
Pfizer&#8217;s dose-optimization studies of once-daily formulations of danuglipron (PF-06882961) met key pharmacokinetic objectives. The study confirmed a formulation and dose that could deliver a competitive efficacy and tolerability profile in Phase 3 testing based on earlier studies of <a href="https://www.benzinga.com/pressreleases/25/04/b44784896/pfizer-provides-update-on-oral-glp-1-receptor-agonist-danuglipron" target="_blank" rel="noreferrer noopener">twice-daily danuglipron</a>.
The stopped trials include:
<ul>
<li>Phase 1, open-label <a href="https://clinicaltrials.gov/study/NCT06568731?term=PF-06882961&amp;limit=10&amp;page=2&amp;rank=16" target="_blank" rel="noreferrer noopener">study</a> to evaluate the multiple-dose pharmacokinetics of danuglipron following oral administration in otherwise healthy adult participants with overweight or obesity.</li>
<li>A two-part phase 1, open-label, fixed-sequence <a href="https://clinicaltrials.gov/study/NCT06567327?term=PF-06882961&amp;limit=10&amp;page=2&amp;rank=18" target="_blank" rel="noreferrer noopener">study</a> to evaluate the multiple-dose pharmacokinetics of danuglipron following oral administration and the effects of steady-state danuglipron on the pharmacokinetics of single oral dose of atorvastatin and rosuvastatin in otherwise healthy adult participants with overweight or obesity.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44777882/benzinga-bulls-and-bears-apple-nike-us-steel-and-the-markets-ride-out-ongoing-volatility" rel="noreferrer noopener">Benzinga Bulls And Bears: Apple, Nike, US Steel — And The Markets Ride Out Ongoing Volatility</a>
The company said that while the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury, which resolved after discontinuation of danuglipron.
After reviewing the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule.
Data from the danuglipron clinical development program will be presented at a scientific forum or submitted for publication in a peer-reviewed journal in the future.
In December 2023, Pfizer reported topline data from the <a href="https://www.benzinga.com/general/biotech/23/12/36041804/this-twice-daily-weight-loss-drug-has-adverse-side-effects-and-pfizer-wants-to-discontinue-it" target="_blank" rel="noreferrer noopener">Phase 2b trial of danuglipron</a>.
The company said the study met its primary endpoint, demonstrating a statistically significant change in body weight from baseline, but danuglipron was tied to "high rates" of mild gastrointestinal side effects, leading to more than half of the patients across all dose groups&nbsp;dropping out from the trial.&nbsp;
Then, Pfizer said the future development of danuglipron will be focused on a once-daily formulation and that it will stop evaluating&nbsp;a twice-daily formulation.
In July 2024, Pfizer selected its preferred once-daily modified-release <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39730398/pfizer-advances-once-daily-weight-loss-pill-as-it-catches-up-to-tap-the-lucrative-market" rel="noreferrer noopener">formulation for danuglipron</a>.
Goldman Sachs noted that it is unlikely to obtain significant tolerability data that could address the main criticisms of the company's Phase 2b <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener">BID (twice daily) study</a>.
The analyst said, "Further to debates that investors have been contemplating relating to "pill burden" — PFE expects that the study would involve and ultimately advance a single pill QD dose format — which, assuming positive results overall, would be the objective in terms of presentation to advance into a Phase 3 registrational study."
"This underpins the company's decision for further development and commitment to their goal of seeking a relevant and competitive presence in the oral obesity therapeutics market."
Price Action: Pfizer is up 0.71% at $22.06 during the session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44775384/fda-approves-argenxs-vyvgart-hytrulo-prefilled-syringe-for-self-injection-for-at-home-use-setting" target="_blank" rel="noreferrer noopener">FDA Approves Argenx&#8217;s Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting</a></li>
</ul>
Image: Shutterstock

Pfizer Discontinues Once-Daily Weight Loss Pill Over Liver Injury In One Patient

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pfizer.com%2F&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=Pfizer+Inc.&amp;index=1&amp;md5=a3aabb03d15f888d5d0e017aac18c91f">Pfizer Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for chronic weight management.
Pfizer's dose-optimization studies of once-daily formulations of danuglipron (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06567327%3Fterm%3DPF-06882961%26limit%3D10%26page%3D2%26rank%3D18&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=NCT06567327&amp;index=2&amp;md5=c65dca627777c49eff20bbbcbeb524a0">NCT06567327</a> and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06568731%3Fterm%3DPF-06882961%26limit%3D10%26page%3D2%26rank%3D16&amp;esheet=54237507&amp;newsitemid=20250413297943&amp;lan=en-US&amp;anchor=NCT06568731&amp;index=3&amp;md5=cb512c8bcc9b4b367d9fcef5079833b5">NCT06568731</a>) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron. While the overall frequency of liver enzyme elevations across the over 1,400 participant safety database of danuglipron is in-line with approved agents in the class, a single asymptomatic participant in one of the dose-optimization studies experienced potential drug-induced liver injury which resolved after discontinuation of danuglipron. After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule.
"Cardiovascular and metabolic diseases including obesity remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR antagonist candidate and other earlier obesity programs," said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research and Development at Pfizer. "While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients."
Data from the danuglipron clinical development program will be presented at a scientific forum or submitted for publication in a peer-reviewed journal in the future.

Pfizer Discontinues Danuglipron Trials for Chronic Weight Management, Focuses on Other Obesity Treatments

Press Releases

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

Dexcom Appoints Jon Coleman as Chief Commercial Officer

ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24

Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting

Pfizer Declares Second-Quarter 2025 Dividend

DXCM

MASI

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Pfizer

空売り

Pfizer (NYSE:PFE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル